ArticleScientific reports2026
Elucidating the burden of dual-sensory impairment in community-based older individuals in a multi-ethnic society.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
We aimed to determine the prevalence, risk factors, patient-centered impact and health-related costs of three types of dual sensory impairment (DSI) in a multi-ethnic older Asian population. In this population-based, cross-sectional study (2017-2022) of 2048 Asian adults aged ≥ 60 years, vision, hearing and olfactory impairments (VI, HI and OI) were assessed using validated clinical tests. DSI types included: VI + HI, VI + OI, and HI + OI. Age-, sex-, and ethnicity-adjusted prevalence rates (2020 Singapore Census) were calculated. Regression analyses identified associated risk factors, impacts and healthcare costs. Of the 2048 participants (mean age ± standard deviation 75.7 ± 7; 49.5% female), prevalence rates of VI + OI, VI + HI, OI + HI were 1.0%, 7.3% and 21.7%, respectively. Older age (odds ratio[OR]1.22) and multimorbidity (OR3.74) were significantly associated with VI + HI, while older age (OR1.23), males (OR3.62), living alone (OR2.37) and current smoking (OR2.51) were associated with higher odds of OI + HI. VI + HI was associated with lower HRQoL-scores (β:- 0.026), while VI + HI (OR2.39) and OI + HI (OR2.10) were associated with lower IADL status. The OI + HI group showed a trend toward higher healthcare costs compared to those without. DSI, particularly OI + HI, is relatively prevalent in older Singaporean adults. Early identification and targeted screening of at-risk groups may mitigate adverse outcomes and healthcare cost, given the global ageing population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.